A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 21-3370
More information available at ClinicalTrials.gov: NCT04657991
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers